UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat HER2 cancers in early trial
Disease control Recruiting nowThis early-phase study tests a combination of two drugs (trastuzumab deruxtecan and azenosertib) in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and…
Matched conditions: UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:48 UTC
-
Could a common heart drug boost cancer treatment?
Disease control Recruiting nowThis study tests whether adding propranolol (a beta-blocker used for heart conditions) to standard chemotherapy and immunotherapy can help people with advanced esophageal or stomach cancer that cannot be surgically removed. The drug may reduce stress hormones that can weaken the …
Matched conditions: UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 17, 2026 04:44 UTC
-
New combo shows promise for tough stomach cancers
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) helps people with advanced stomach or esophageal cancer live longer without their disease getting worse. About 224 adults whose cancer has a specific marker (PD-…
Matched conditions: UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New immune cocktail targets tough stomach cancers
Disease control Recruiting nowThis study tests a mix of immune cells (agenT-797) and three immunotherapy drugs (botensilimab, balstilimab, ramucirumab) plus chemotherapy (paclitaxel) for people with advanced stomach, esophageal, or gastro-esophageal junction cancer that has worsened after one prior treatment.…
Matched conditions: UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug combo shows promise for tough stomach cancers
Disease control Recruiting nowThis early-phase study tests two drugs, pembrolizumab and lenvatinib, in about 15 people with advanced stomach or gastroesophageal cancer that has spread or can't be surgically removed. Pembrolizumab helps the immune system attack cancer cells, while lenvatinib blocks enzymes tha…
Matched conditions: UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New chemo cocktail aims to extend life in hard-to-treat stomach cancers
Disease control Recruiting nowThis study compares two chemotherapy combinations for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. About 382 participants will receive either the standard FOLFOX chemo (with or without the immunotherapy nivolumab…
Matched conditions: UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 04, 2026 16:18 UTC